Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > MTD and the FDA

<< Previous

Bullboard Posts

Next >>

Comment by AMoschittoon Aug 06, 2021 1:05pm

99 Views

Post# 33663874

RE:RE:RE:RE:RE:RE:MTD and the FDA

On this point, with patients who may have developed resistance to taxol based on their previous treatment history... would bypassing the MDR pump still be effective in the way they talked about in the June presentation? I went to look back at that slide but they have
taken it out of the current presentation.

Curious if people here have thoughts about that as a potential disadvantage of this population (of course acknowledging more sortilin expression in late-stage cancers as making these patients ideal for TH1902 as well).

<< Previous

Bullboard Posts

Next >>

5 steps to mastering risk management in the stock market